Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation
This study presents the first documented case of anti-emicizumab antibodies in AHA. Our study provides insights into ADA development against emicizumab, emphasizing the need for monitoring tools. The developed method enables comprehensive evaluation of ADAs, aiding in personalized treatment strategies. These findings contribute to understanding emicizumab's immunogenicity profile in AHA, facilitating its optimized clinical use.
Authors
- Samhitha Urs Ramaraje Urs (ORCID: https://orcid.org/0000-0003-0318-7483)
- Isabell Matuschek
- Claudia Klein
- Nadja Sereda
- Ann‐Cristin Berkemeier
- Jens Müller (ORCID: https://orcid.org/0000-0001-7713-9631)
- Behnaz Pezeshkpoor (ORCID: https://orcid.org/0000-0002-4796-3424)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
- Janine Becker-Gotot (ORCID: https://orcid.org/0000-0003-1190-2133)
- Sneha Singh (ORCID: https://orcid.org/0000-0003-2983-5733)
- Natascha Marquardt
Institutions
- University of Bonn (DE)
- University Hospital Bonn (DE)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1016/j.jtha.2024.10.003
- Citations
- 4
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Octapharma